LifeStance Health Group, Inc. (LFST) Q3 2024 Earnings Call Transcript Summary
LifeStance Health Group, Inc. (LFST) Q3 2024 Earnings Call Transcript Summary
Adjusted EBITDA rose to $31 million, a 110% increase from previous year.The following is a summary of the LifeStance Health Group, Inc. (LFST) Q3 2024 Earnings Call Transcript:
以下是LifeStance健康集團（LFST）2024年第三季度業績會議呼叫記錄摘要：
Financial Performance:
財務表現:
Q3 revenue reached $313 million, up 19%, with increased revenue per visit and visit volumes.
Adjusted EBITDA rose to $31 million, a 110% increase from previous year.
第三季度營業收入達到了31300萬美元，增長了19%，每次就診收入和就診次數均有所增加。
調整後的EBITDA從上一年的3100萬美元增長了110%。
Business Progress:
業務進展:
Digital patient check-in tool implemented in 11 states, with full rollout by mid-2025.
Added 285 clinicians in Q3, expanding clinician base by 13% YoY.
數字化患者簽到工具在11個州實施，預計將於2025年中全面推廣。
第三季度新增285名臨床醫師，年度增長率達到13%。
Opportunity:
機會：
National rollout of digital patient check-in tool to enhance patient satisfaction.
Increased hiring of clinicians due to high demand for mental health services.
全國推出數字化患者登記工具以提高患者滿意度。
由於精神健康服務需求旺盛，增加了臨床醫生的聘用。
Risk:
風險：
Reduced rates from one payer affecting revenues, anticipated pressure due to CMS rate proposal for 2025.
Collection challenges due to changes in healthcare collection practices.
來自一家付款人的降低費率影響了營業收入，由於康哲藥業提出的2025年費率建議，預計將面臨壓力。
由於醫療保健收款方式變化，導致收款挑戰。
Financial Performance:
財務表現:
LifeStance reported Q3 revenue of $313 million, a growth of 19% compared to the previous year. They attribute this to higher total revenue per visit and increased visit volumes.
Center margin for the quarter stood at $100 million, up 32% year-over-year, primarily due to higher total revenue per visit and greater visit volumes.
The company achieved adjusted EBITDA of $31 million, up 110% from the previous year, driven by improvement in center margin and lower than expected G&A spending.
Despite the impact from changed health care collections and some payer delays, the company expects DSO to improve further.
Cash position improved, ending the quarter with $103 million in cash, up from year-to-date generation of about $30 million in free cash.
Raised full-year revenue and profitability outlook based on Q3 performance.
LifeStance報告2025年第三季度營業收入$31300萬，比去年同期增長19%。他們將這歸因於每次就診的總收入增加以及就診量增加。
本季度中心利潤爲$10000萬，同比增長32%，主要是由於每次就診的總收入增加和就診量增加。
公司實現了經調整的EBITDA爲3100萬美元，比去年同期增長110%，主要受益於中心利潤率的改善和較預期更低的G&A支出。
儘管受到醫療保健收款變化和一些付款方延遲的影響，公司預計DSO將進一步改善。
現金狀況得到改善，在本季度末現金爲10300萬美元，較年初創造的約3000萬美元的自由現金有所增長。
基於第三季度表現，提高了全年營業收入和盈利前景。
Business Progress:
業務進展:
LifeStance has continued to roll out its new digital patient check-in tool, implemented in 11 states with plans for a national rollout by mid-2025.
Continued clinician growth with a net addition of 285 clinicians in Q3, bringing the total to 7,269, a 13% increase year-over-year.
Shift in payroll cycle for clinicians, moving to a biweekly from monthly, which reflects a dedication to improving the clinician experience despite a $15 million negative cash flow impact in Q4.
Company keeps expanding geographic footprint, currently operating in 33 states and over 550 centers.
LifeStance繼續推出其新的數字化患者登記工具，在11個州實施，並計劃在2025年年中全國推出。
第三季度臨床醫師數量持續增長，淨增加285名臨床醫師，總數達7269名，同比增長13%。
臨床醫師工資週期的轉變，從每月一次變爲每兩週一次，體現了改善臨床醫師體驗的決心，儘管在第四季度造成了1500萬美元的負現金流影響。
公司不斷擴大地理範圍，目前在33個州運營，並擁有超過550箇中心。
Opportunities:
機會：
Ongoing national rollout of a digital patient check-in tool enhancing patient satisfaction and operational efficiencies.
Committed to increased clinician hiring as demand for mental health services remains high.
Positive engagements with multiple payers have improved rate increases contributing to revenue growth.
正在全國範圍內推出數字化患者登記工具，提升患者滿意度和運營效率。
致力於增加臨床人員的招聘，因爲對心理健康服務的需求仍然很高。
與多家付款方的積極互動改善了費率增長，有助於營業收入增長。
Risks:
風險：
Impact of reduced rates from a single outlier payer with above-market reimbursement starting to affect the financial results. Anticipated pressure on total revenue per visit in the near future due to further negotiated rate reductions and the CMS rate proposal for 2025 which suggests a reduction of almost 3%.
Continued collection challenges linked to changes in healthcare collection practices and payer system updates.
由於來自一個單一異常付款方的降低費率對高市場補償率的影響開始影響財務結果。由於進一步協商降低費率以及康哲藥業2025年費率建議幾乎降低3％，預計未來不久會出現總訪問費用的壓力。
與醫療保健收款實踐變化和付款方系統更新相關的持續收款挑戰。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。